Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec AG Reports H1 2013 Results

Published: Friday, August 09, 2013
Last Updated: Friday, August 09, 2013
Bookmark and Share
Company predicts top-line growth in the second half of the year 2013 due to expected milestones.

Evotec AG reported financial results and corporate updates for the first half of 2013.

Revenues excluding milestones, upfronts and licences up 6% compared to the first half of 2012
- H1 2013 revenues amounted to EUR 36.7 m (2012: EUR 42.0 m); revenues excluding milestones, upfronts and licences were up 6% compared to H1 2012 revenues on a like-for-like basis
- Operating loss at EUR 4.4 m due to low milestone revenues in H1 2013
- Stable liquidity position at EUR 56.1 m
- High and stable equity ratio at 67.7%

Progress in EVT Execute business and new EVT Integrate/EVT Innovate alliances support innovation efficiency strategy
- New collaboration with Dow AgroSciences on Cellular Target Profiling
- Extension of alliance with Genentech
- Extension of Active Biotech collaboration (after period-end)
- Important strategic expansion of EVT Execute compound management capability: New site in Branford, US
- Significant milestone achievement with Boehringer Ingelheim
- TargetPGB (Peptidoglycan Biosynthesis): New collaboration with Harvard University to identify and develop a new class of antibacterials
- TargetKDM (Lysine Demethylases): New collaboration with Dana Farber's Belfer Institute for Applied Cancer Science to explore epigenetic oncology targets
- New hormone identified to treat diabetes as part of Evotec's CureBeta initiative
- Significant clinical data points ahead in 2013/2014/2015

Indian operations to be discontinued at the end of September 2013 (after period-end)

Financial guidance for 2013 confirmed
- Revenues are expected to grow to a level between EUR 90-100 m
- Operating result before impairment and changes in contingent consideration, if any, is expected to improve over 2012
- R&D expenditure is expected to be around EUR 10 m
- Strong liquidity position above EUR 60 m

Others
- Dr Flemming Ørnskov resigned as Chairman and member of the Supervisory Board
- Dr Walter Wenninger appointed as new Chairman of the Supervisory Board and Dr Claus Braestrup elected as a member of the Supervisory Board
- Strengthening of the management capacities with the following appointments (after period-end):
Dr Adrian Howd, Executive Vice President, Head of Neurology & Corporate Development; and
Dr Bastian Sauer-Odendahl, Global Head of Human Resources
- Strengthening of business development activities in Japan through the appointment of Masahiko Ohtani as Vice President Business Development (after period-end)


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Extends Integrated Drug Discovery Alliance With Genentech
Evotec and Genentech will continue their drug discovery alliance for a further three years.
Tuesday, May 24, 2016
Evotec, Ex Scientia Partner
Evotec and ex scientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics.
Tuesday, April 26, 2016
Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec AG Increases Its Revenue Guidance For 2015
All other elements of the Company’s financial guidance as of 12 May 2015 are confirmed.
Tuesday, September 15, 2015
Evotec Enters into Agreement with Pfizer
Licence and collaboration agreement in the field of tissue fibrosis.
Friday, September 11, 2015
Evotec, Apeiron Biologics and Sanofi Collaborate
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, have announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.
Monday, August 10, 2015
Evotec & Facio Partner
Facio partners with Evotec and initiates FSHD drug discovery programme.
Friday, May 08, 2015
Evotec and C4XD Enter Collaboration
Collaboration leverages the breadth & experience of Evotec's drug discovery infrastructure across chemistry & biology.
Tuesday, January 20, 2015
Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec and Sanofi Enter into Exclusive Negotiations
Goal to improve innovation effectiveness in drug discovery and pre-clinical development.
Thursday, December 04, 2014
Evotec And The Jain Foundation Expand Collaboration
The collaboration marks the start of multiple drug screening programmes.
Monday, September 15, 2014
Evotec, Medicines for Malaria Announce Compound Management Collaboration
The collaboration will support MMV’s Malaria and Pathogen Box initiatives.
Tuesday, August 19, 2014
Evotec, Fraunhofer in Drug Discovery Collaboration
The exclusive, strategic collaboration will combine the relevant platforms of both organisations, focusing on several disease areas.
Tuesday, July 08, 2014
Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
Company receives milestone payment of € 1.0 m.
Thursday, June 19, 2014
Evotec to Establish an Anti-infectives Platform with the Acquisition of Euprotec Ltd
Adds key know-how and infectious disease therapeutic area capabilities.
Thursday, May 29, 2014
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Study Identifies How Brain Connects Memories Across Time
UCLA Neuroscientists have boost ability of aging brain to recapture links between related memories.
3-D Atomic Structure of Cholesterol Transporter
Researchers at UTSW have determined the 3-D atomic structure of a human sterol transporter that helps maintain cholesterol balance.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Can We Break the Link Between Obesity and Diabetes?
Columbia University researchers identify a key molecule involved in the development of type 2 diabetes.
Fungi – A Promising Source Of Chemical Diversity
Moulds and plants share similar ways in alkaloid biosynthesis .
How Prions Kill Neurons: New Culture System Shows Early Toxicity to Dendritic Spines
Boston University researchers have developed a cell culture system to study prions.
Great Migration and African-American Genomic Diversity
Study examines genetic data to analyze regional differences in ancestry.
Faster, More Efficient CRISPR Editing
UC Berkeley scientists have developed a quicker and more efficient method to alter the genes of mice with CRISPR-Cas9, simplifying a procedure growing in popularity because of the ease of using the new gene-editing tool.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!